← ANALYST RATINGS · TIPRANKS
Cerus (CERS): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $4.50, the highest $5.00, the lowest $4.00. The average is +106.4% from the last price of $2.18.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −8.3% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | −8.3% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | +14.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | +14.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Buy | +14.7% | Upgrade | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.50−16.7% | Hold | +14.7% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $5.00 | Buy | +129.4% | Reiterated | 28.08.26on TipRanks 09:11 | −2.3%next day −0.1% · 5 days −2.4% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $4.00 | Buy | +83.5% | Reiterated | 14.08.26on TipRanks 07:35 | +5.1%next day +0.1% · 5 days −4.3% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | — | Buy | — | Reiterated | 01.05.26on TipRanks 11:55 | +33.7%next day +0.4% · 5 days −6.4% | ↗ |
| Ross Osborn★★★★★★★★★★#11870 · hits 30% · avg −6.3% | Cantor Fitzgerald | $4.00 | Buy | +83.5% | Reiterated | 07.11.25on TipRanks 21:10 | −8.0%next day +2.9% · 5 days −2.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Cerus
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $4.50 at a price of $2.38 (+89.1%); now: $4.50 at $2.18 (+106.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 2 | 2 | 1 | 1 | 1 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.01 (from $-0.02 to $0.00). Last quarter: $-0.01.
Sales
Next quarter’s sales estimate — $63M (from $62M to $64M). Last quarter: $57M.
Best top-analyst consensus in the sector · Healthcare
About Cerus
- CEO: Vivek K. Jayaraman
- Employees: 268
- 1220 Concord Avenue, Concord, CA, 94520, US
- www.cerus.com
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Data from the stock’s TipRanks forecast page, read 78 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗